ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:

• Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancer
• The importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patients
• Results from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interaction

Presenters:

Hope S. Rugo, MD, FASCO
Director, Women’s Cancer Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology
University of California, San Francisco
San Francisco, California

Nerea Lopetegui-Lia, MD
Assistant Professor
Division of Medical Oncology, Breast Section
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.

Link to full program: 
https://bit.ly/4x4u5AT

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.